December 10, 2019
Six months after calling off one of its PIII Ninlaro (ixazomib) trials, Takeda Pharmaceutical on December 7 unveiled detailed data from the failed study, which investigated the multiple myeloma drug in systemic light-chain (AL) amyloidosis. In June, Takeda said that...read more